Skip to Content

Bristol-Myers Squibb Co BMY Stock Quote

| Rating as of

NYSE: BMY

Morningstar‘s Stock Analysis BMY

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Bristol's Major Patent Losses Will Likely Limit Growth, but Its Pipeline Looks Strong

Damien Conover Sector Director

Business Strategy and Outlook

| Damien Conover |

Adept at partnerships and acquisitions, Bristol-Myers Squibb has built a strong portfolio of drugs and a robust pipeline. This strategy is seen with its large acquisition of Celgene, which netted the firm an excellent pipeline and a strong entrenchment in blood cancer. We believe the strong overall pipeline helps support its wide moat.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BMY

Company Profile BMY

Business Description

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Contact
430 East 29th Street, 14th Floor
New York, NY, 10016
Industry Drug Manufacturers - General
Employees 32,200

Related Articles BMY

FAQs for Bristol-Myers Squibb Co Stock

Yes. BMY has a forward dividend yield of 2.70%. See BMY’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

BMY’s market cap is 169.94 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

BMY’s stock style is Large Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

BMY’s price/sales is 3.71.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

BMY’s price/forward earnings is 10.10.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

BMY’s price/book is 5.20.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See BMY’s valuation ratios compared to the Market Index.

BMY’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare BMY’s historical performance against its industry peers and the overall market.